Syensqo Acquires Ceramides Specialist Jinyoung Bio

Syensqo announced the acquisition of JinYoung Bio, a specialty cosmetic ingredients supplier based in South Korea. This investment expands Syensqo’s portfolio toward more natural and high-value specialty skin care solutions with functional and active ingredients.

Ceramides, the flagship product line within Jinyoung Bio’s portfolio, are produced through biotechnology via a fermentation process, which aligns with Syensqo’s renewable materials and biotechnology growth goals. The addition of Jinyoung Bio’s technology will extend Syensqo’s product portfolio into biomimetic ceramides for skin care and hair care applications, as well as a range of biobased functional ingredients used in skincare and color cosmetic applications.

"This acquisition reflects our deep commitment to innovation and our focus on sustainable solutions leveraging the power of biotechnology," commented Ilham Kadri, CEO of Syensqo. "We are dedicated to making a meaningful impact in the beauty industry, addressing critical environmental and societal challenges with groundbreaking circular solutions."

Syensqo’s beauty care business aims to grow Jinyoung Bio’s commercial and technical capabilities through its customer access, formulation and application expertise, and marketing capabilities. The company plans to launch its first product from the ceramides line and four functional ingredients in Q2 2024, supporting the aim of Syensqo’s Home & Beauty Care business to grow twice as fast as the market. 

Company

Syensqo

rue de la Fusée 98
B-1130 Brussels
Belgium

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read